Nevro Medical (NVRO): יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Nevro Corp. (NVRO) operates in the non-cyclical neurostimulation segment, where demand for procedures remains stable regardless of market fluctuations. This chart illustrates the current share value with an EV/EBITDA ratio of . The company relies on its exclusive HF10 technology, which provides significant pricing power. However, expansion is limited by US market saturation and a potential decline in profitability due to the costs of launching new products.

The EV/EBITDA multiple compares the total value of a company's assets and debt with its operating profit before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA dynamics of a capital-intensive company, an investor determines the degree of business overvaluation and identifies points of fundamental price reversal. For Nevro Corp. (NVRO), this indicator remains stable due to steady demand for spinal cord stimulation systems and the low sensitivity of the medical sector to economic cycles.